Breaking News Instant updates and real-time market news.

TBPMF

Tetra Bio Pharma

$0.00 /

+ (+0.00%)

08:27
03/23/20
03/23
08:27
03/23/20
08:27

Tetra Bio Pharma says in 'good position' to maintain drug development programs

Tetra Bio-Pharma announced that it has ensured that all of its employees work under conditions that comply with federal and provincial public health recommendations. Additionally, following the completion of its $17.8M financing in February and early March, the Company is in a good position to maintain its drug development programs. Regulatory activities have not slowed down despite the COVID-19 crisis. These activities are now performed by Tetra's employees from their home offices. Tetra confirms that it will continue all planned Clinical Trial Applications, DIN, veterinary drug clinical trial applications and Pre-Submission meetings in Canada and Investigational New Drug Applications, veterinary IND applications, Pre-IND meetings, Orphan Drug Designation applications in the United States. European regulatory activities will also continue. Tetra's clinical research team is working to increase the number of clinical sites in Canada and the USA so that it can accelerate the enrolment of patients when the crisis is over. To date the ophthalmic clinical trial has been moving along as per expected timelines. Half of the patient dogs have completed the treatment phase of the study. There was no treatment related adverse events. Tetra expects to complete this trial in this fiscal quarter or early in fiscal Q3 and will then report the key outcomes of the study. The corporation has already begun planning the second trial for the treatment of canine indolent corneal ulcers. This second trial will involve regulatory filings in both Canada and the USA. The IND-enabling toxicology studies with HU308 for the human ocular trials are continuing as planned. During this crisis period, Tetra will be submitting both an IND and CTA to initiate a clinical trial in Canada and the USA for its Orphan Drug HCC011. The corporation will continue forward with its PIND meeting request to discuss with the FDA the marketing requirements for this Orphan Drug that would benefit from FDA's expedited programs as well as the 505(b)(2) NDA regulatory pathway. Serenity and Reborn activities will be slowed by the crisis. However, the extent of any delays in the clinical activities will be a result of the ultimate effect that this crisis has on factors such as availability of physicians, clinics and enrolment. This is fully understandable as hospital-based physicians have been mobilized to treat individuals infected by the COVID-19 virus, which we all consider to be urgent. That is why Company immediately began procedures to increase the number of clinical sites. Tetra has prioritized obtaining critical clinical research data during this period that had previously been planned for late 2020. The clinical outcomes from these studies will provide important scientific and medical information on CAUMZTD and HCC011. This information is required for the marketing application for any new drug. Tetra has communicated with all of its drug suppliers, including those that produce THC, CBD, HU308 and PPP001. Current assessment by these firms is that the COVID-19 crisis will not significantly affect supply of the clinical research medications. Tetra's main QIXLEEF clinical site should be minimally affected by the crisis as it is a private clinic and not a hospital. Panag Pharma and TALLC research and development activities will be moving along as planned. CB2 Therapeutics pre-commercialization activities will also continue as planned.

TODAY'S FREE FLY STORIES

Hot Stocks
Kayne Anderson MLP says had $506M of cash on balance sheet as of Mar. 27 » 08:20
03/30/20
03/30
08:20
03/30/20
08:20
KYN

Kayne Anderson MLP

$3.46 /

-0.405 (-10.49%)

Kayne Anderson…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Technical Analysis
Nasdaq 100 Index: Pivot points » 08:20
03/30/20
03/30
08:20
03/30/20
08:20
NDX

Nasdaq 100 Index

$0.00 /

+ (+0.00%)

The following are the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Hot Stocks
Conn's announces resignation of Davis as President, Credit and Collections » 08:19
03/30/20
03/30
08:19
03/30/20
08:19
CONN

Conn's

$5.12 /

-0.185 (-3.49%)

In a regulatory filing…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Kayne Anderson Midstream/Energy Fund says has $146M of cash on balance sheet » 08:19
03/30/20
03/30
08:19
03/30/20
08:19
KMF

Kayne Anderson Midstream/Energy Fund

$2.95 /

-0.27 (-8.40%)

Kayne Anderson…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Recommendations
Wyndham Destinations price target lowered to $40 from $66 at Oppenheimer » 08:19
03/30/20
03/30
08:19
03/30/20
08:19
WYND

Wyndham Destinations

$24.94 /

-0.62 (-2.43%)

Oppenheimer analyst Ian…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Service Properties announces efforts to mitigate COVID-19, cuts dividend » 08:18
03/30/20
03/30
08:18
03/30/20
08:18
SVC

Service Properties

$6.95 /

+0.12 (+1.76%)

Service Properties…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Microlab DCC Series POI solution chosen for Raymond James Stadium » 08:18
03/30/20
03/30
08:18
03/30/20
08:18
WTT

Wireless Telecom Group Inc

$0.81 /

+ (+0.00%)

Microlab, a Wireless…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Recommendations
Live Nation price target lowered to $65 from $85 at Cowen » 08:18
03/30/20
03/30
08:18
03/30/20
08:18
LYV

Live Nation

$47.10 /

+1.08 (+2.35%)

Cowen analyst Stephen…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Global Payments price target raised to $174 from $162 at RBC Capital » 08:17
03/30/20
03/30
08:17
03/30/20
08:17
GPN

Global Payments

$144.67 /

-8.88 (-5.78%)

RBC Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
electroCore announces 510(k) clearance of gammaCore label expansion » 08:17
03/30/20
03/30
08:17
03/30/20
08:17
ECOR

electroCore

$0.41 /

-0.06 (-12.90%)

electroCore announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Mirati Therapeutics price target lowered to $105 from $129 at Oppenheimer » 08:16
03/30/20
03/30
08:16
03/30/20
08:16
MRTX

Mirati Therapeutics

$76.30 /

-3.96 (-4.93%)

Oppenheimer analyst Jay…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Chuy's withdraws 2020 financial guidance » 08:16
03/30/20
03/30
08:16
03/30/20
08:16
CHUY

Chuy's

$10.71 /

-1.14 (-9.62%)

Due to the ongoing…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Community Bank System downgraded to Market Perform from Outperform at Hovde Group » 08:16
03/30/20
03/30
08:16
03/30/20
08:16
CBU

Community Bank System

$57.42 /

+0.03 (+0.05%)

Hovde Group analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
KB Home price target lowered to $26 from $42 at Raymond James » 08:16
03/30/20
03/30
08:16
03/30/20
08:16
KBH

KB Home

$17.91 /

-1.04 (-5.49%)

Raymond James analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Chuy's says 92 restaurants have transitioned to off-premise operating model » 08:15
03/30/20
03/30
08:15
03/30/20
08:15
CHUY

Chuy's

$10.71 /

-1.14 (-9.62%)

Chuy's Holdings…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Cowen biotechnology analyst to hold an analyst/industry conference call » 08:14
03/30/20
03/30
08:14
03/30/20
08:14

Biotech Analyst Werber…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Hot Stocks
Rapt Therapeutics reports Q4 EPS (87c), two est. (69c) » 08:14
03/30/20
03/30
08:14
03/30/20
08:14
RAPT

Rapt Therapeutics

$19.52 /

+0.83 (+4.44%)

"2019 was an…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
CME Group upgraded to Outperform from Market Perform at Raymond James » 08:14
03/30/20
03/30
08:14
03/30/20
08:14
CME

CME Group

$171.42 /

-3.49 (-2.00%)

Raymond James analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Spectrum Brands price target lowered to $50 from $80 at Oppenheimer » 08:14
03/30/20
03/30
08:14
03/30/20
08:14
SPB

Spectrum Brands

$35.10 /

-2.83 (-7.46%)

Oppenheimer analyst Ian…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Mogo Finance price target lowered to $4 from $7 at B. Riley FBR » 08:13
03/30/20
03/30
08:13
03/30/20
08:13
MOGO

Mogo Finance

$0.90 /

-0.17 (-15.89%)

B. Riley FBR analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Ericsson upgraded to Outperform from Market Perform at Cowen » 08:13
03/30/20
03/30
08:13
03/30/20
08:13
ERIC

Ericsson

$7.42 /

-0.175 (-2.30%)

Cowen analyst Paul…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Neos Therapeutics operates under reduction of hours amid COVID-19 » 08:13
03/30/20
03/30
08:13
03/30/20
08:13
NEOS

Neos Therapeutics

$0.80 /

-0.0302 (-3.64%)

Jerry McLaughlin,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
AAR Corp. adopts limited duration stockholder rights plan » 08:13
03/30/20
03/30
08:13
03/30/20
08:13
AIR

AAR Corp.

$17.89 /

-1.94 (-9.78%)

AAR Corp. announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Container Store to reduce workforce, adjust store operations due to COVID-19 » 08:12
03/30/20
03/30
08:12
03/30/20
08:12
TCS

Container Store

$3.25 /

-0.085 (-2.55%)

Container Store Group…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Franklin Covey price target lowered to $32 from $45 at B. Riley FBR » 08:12
03/30/20
03/30
08:12
03/30/20
08:12
FC

Franklin Covey

$15.16 /

-1.97 (-11.50%)

B. Riley FBR analyst Zach…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.